OBJECTIVE: To investigate how blood lipid levels are related to disease activity, clinical characteristics, and serum levels of tumor necrosis factor alpha (TNF alpha) and its soluble type 1 and 2 receptors, sTNFR1 and sTNFR2, in systemic lupus erythematosus (SLE). METHODS: Fasting blood samples were obtained from an unselected cohort of SLE patients at Karolinska Hospital (n = 208, mean +/- SD age 45.7 +/- 14.2 years). Disease activity was estimated using the SLE Disease Activity Measure (SLAM). Levels of circulating TNF alpha, sTNFR1, and sTNFR2 were determined by enzyme-linked immunosorbent assay. Blood lipid levels obtained after overnight fasting were analyzed by routine chemistry. RESULTS: Triglyceride (TG) levels were associated with the SLAM score (r = 0.48, P < 0.0001) and with the activities of TNF alpha (r = 0.29, P = 0.0001), sTNFR1 (r = 0.38, P < 0.0001), and sTNFR2 (r = 0.40, P < 0.0001). High-density lipoprotein (HDL) levels were negatively associated with the SLAM score (r = -0.27, P = 0.0003) and with the activities of TNF alpha (r = -0.15, P = 0.04) and sTNFR2 (r = -0.19, P = 0.01). High levels of TGs, total cholesterol, TNF alpha, sTNFR1, and sTNFR2 all showed close correlations with the presence of nephritis and arterial disease (P < 0.05). In multiple logistic regression models, the TNF alpha activity and TG levels were independent determinants (P = 0.003 for both) of active disease (SLAM score > or =7). CONCLUSION: Dyslipoproteinemia with high TG/low HDL levels correlates with disease activity in SLE, and enhanced activity in the TNFalpha/sTNFR system seems to be an important underlying factor. Both dyslipoproteinemia and enhanced activity of the TNF alpha system are closely related to cardiovascular and renal manifestations in SLE, and thus both may serve as markers of more severe disease.
OBJECTIVE: To investigate how blood lipid levels are related to disease activity, clinical characteristics, and serum levels of tumor necrosis factor alpha (TNF alpha) and its soluble type 1 and 2 receptors, sTNFR1 and sTNFR2, in systemic lupus erythematosus (SLE). METHODS: Fasting blood samples were obtained from an unselected cohort of SLEpatients at Karolinska Hospital (n = 208, mean +/- SD age 45.7 +/- 14.2 years). Disease activity was estimated using the SLE Disease Activity Measure (SLAM). Levels of circulating TNF alpha, sTNFR1, and sTNFR2 were determined by enzyme-linked immunosorbent assay. Blood lipid levels obtained after overnight fasting were analyzed by routine chemistry. RESULTS:Triglyceride (TG) levels were associated with the SLAM score (r = 0.48, P < 0.0001) and with the activities of TNF alpha (r = 0.29, P = 0.0001), sTNFR1 (r = 0.38, P < 0.0001), and sTNFR2 (r = 0.40, P < 0.0001). High-density lipoprotein (HDL) levels were negatively associated with the SLAM score (r = -0.27, P = 0.0003) and with the activities of TNF alpha (r = -0.15, P = 0.04) and sTNFR2 (r = -0.19, P = 0.01). High levels of TGs, total cholesterol, TNF alpha, sTNFR1, and sTNFR2 all showed close correlations with the presence of nephritis and arterial disease (P < 0.05). In multiple logistic regression models, the TNF alpha activity and TG levels were independent determinants (P = 0.003 for both) of active disease (SLAM score > or =7). CONCLUSION:Dyslipoproteinemia with high TG/low HDL levels correlates with disease activity in SLE, and enhanced activity in the TNFalpha/sTNFR system seems to be an important underlying factor. Both dyslipoproteinemia and enhanced activity of the TNF alpha system are closely related to cardiovascular and renal manifestations in SLE, and thus both may serve as markers of more severe disease.
Authors: Kathleen E Sullivan; April Suriano; Kelly Dietzmann; Janice Lin; Daniel Goldman; Michelle A Petri Journal: Clin Immunol Date: 2007-02-05 Impact factor: 3.969
Authors: I Parodis; H Ding; A Zickert; L Arnaud; A Larsson; E Svenungsson; C Mohan; I Gunnarsson Journal: Scand J Rheumatol Date: 2016-12-15 Impact factor: 3.641
Authors: Carmen M Gurrola-Díaz; Sergio Sánchez-Enriquez; Edith Oregon-Romero; Pedro M García-López; Pedro Garzón de la Mora; Blanca E Bastidas-Ramírez; Mercedes González-Hita; José F Muñoz-Valle Journal: J Clin Lab Anal Date: 2009 Impact factor: 2.352
Authors: Sylwia M Figarska; Stefan Gustafsson; Johan Sundström; Johan Ärnlöv; Anders Mälarstig; Sölve Elmståhl; Tove Fall; Lars Lind; Erik Ingelsson Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Anna Hellquist; Marco Zucchelli; Cecilia M Lindgren; Ulpu Saarialho-Kere; Tiina M Järvinen; Sari Koskenmies; Heikki Julkunen; Päivi Onkamo; Tiina Skoog; Jaana Panelius; Anne Räisänen-Sokolowski; Taina Hasan; Elisabeth Widen; Iva Gunnarson; Elisabet Svenungsson; Leonid Padyukov; Ghazaleh Assadi; Linda Berglind; Ville-Veikko Mäkelä; Katja Kivinen; Andrew Wong; Deborah S Cunningham Graham; Timothy J Vyse; Mauro D'Amato; Juha Kere Journal: PLoS One Date: 2009-12-07 Impact factor: 3.240